Evidence mapPaperPMID 39967347Full record

ArticleCancer medicine2025

Multi-Institutional MR-Derived Radiomics to Predict Post-Exenteration Disease Recurrence in Patients With T4 Rectal Cancer.

Niall J O'Sullivan, Fariba Tohidinezhad, Hugo C Temperley, Mirac Ajredini, Bedirye Koyuncu Sokmen, Rumeysa Atabey, Leyla Ozer, Erman Aytac, Alison Corr, Alberto Traverso and 2 more

Abstract readMulticenter Study
In one paragraph

Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Niall J O'SullivanDepartment of Radiology, St. James's Hospital, Dublin, Ireland.ORCID https://orcid.org/0000-0002-6241-7819
Fariba TohidinezhadDepartment of Radiation Oncology (Maastro Clinic), School for Oncology and Reproduction (GROW), Maastricht University Medical Centre, Maastricht, the Netherlands.
Hugo C TemperleyDepartment of Radiology, St. James's Hospital, Dublin, Ireland.
Mirac AjrediniAcibadem University, Atakent Hospital Gastrointestinal Oncology Unit, Istanbul, Turkey.
Bedirye Koyuncu SokmenAcibadem University, Atakent Hospital Gastrointestinal Oncology Unit, Istanbul, Turkey.
Rumeysa AtabeyAcibadem University, Atakent Hospital Gastrointestinal Oncology Unit, Istanbul, Turkey.
Leyla OzerAcibadem University, Atakent Hospital Gastrointestinal Oncology Unit, Istanbul, Turkey.
Erman AytacAcibadem University, Atakent Hospital Gastrointestinal Oncology Unit, Istanbul, Turkey.ORCID https://orcid.org/0000-0002-8803-0874
Alison CorrDepartment of Radiology, St. James's Hospital, Dublin, Ireland.
Alberto TraversoSchool of Medicine, Libera Università Vita-Salute San Raffaele, Milan, Italy.
James F MeaneyDepartment of Radiology, St. James's Hospital, Dublin, Ireland.
Michael E KellySchool of Medicine, Trinity College Dublin, Dublin, Ireland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionLocal recurrence and distant metastasis remain a concern in advanced rectal cancer, with up to 10% and 20%-30% of patients suffering local and distal progression, respectively. Radiomics refers to a novel technology that extracts and analyses quantitative imaging features from images, which can be subsequently used to develop and test clinical models predictive of outcomes. We aim to develop and test an MRI-based radiomics nomogram predictive of disease recurrence in patients with T4 rectal cancer.

methodsWe conducted a multi-institutional retrospective analysis of 55 patients with T4 rectal cancer treated with neoadjuvant chemoradiotherapy followed by exenterative surgery. Radiomic features were extracted from pre-treatment T2-weighted MRI scans and used to construct predictive models. The top-performing radiomic signatures were identified, and internal validation with 1000 bootstrap samples was performed to calculate optimism-corrected performance measures.

resultsTwo radiomic signatures were identified as strong predictors of post-operative disease recurrence. The best-performing model achieved an optimism-corrected AUC of 0.75, demonstrating good discriminative ability. Calibration plots showed a satisfactory fit of the predictions to the actual rates, and decision curve analyses confirmed the positive net benefit of the models.

conclusionThe MRI-based radiomics nomogram provides a promising tool for predicting disease recurrence in T4 rectal cancer patients post-exenteration. This model could improve risk stratification and guide more personalized treatment strategies. Further studies with larger cohorts and external validation are needed to confirm these findings and enhance the model's generalizability.

Indexed as

Magnetic Resonance ImagingNeoplasm Recurrence, LocalRectal NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedNeoadjuvant TherapyNeoplasm StagingNomogramsRadiomicsRetrospective Studiesadvanced rectal cancerMRIoncologyRadiomicsrecurrence

Identifiers

PMID39967347
PMCPMC11836347

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.